Age-Related Macular Degeneration Clinical Trial
Official title:
Unlocking Limitations Through Arts: A Mixed Methods Study on the Effectiveness of an Expressive Arts-based Intervention on Psychosocial Wellbeing of Adults With Age-related Visual Impairment
NCT number | NCT05675150 |
Other study ID # | 17611122 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2023 |
Est. completion date | December 31, 2025 |
Age-related Macular Degeneration (AMD) is an age-related eye disease resulting in vision loss. Persons with AMD not only experience a gradual loss of ability in independent living, but also profound impairment in psychosocial well-being.The multimodal, expressive arts-based intervention (EXABI) that emphasizes imagination and creativity can be an engaging, enjoyable, and safe process of empowerment. This study aims to investigate the effectiveness and process of an expressive arts-based intervention in enhancing psychosocial wellness and adjustment to gradual vision loss of persons with AMD. This current study will adopt a 2-arm randomized controlled design with treatment-as-usual control. Upon screening for inclusion exclusion criteria, baseline data will be collected; and eligible participants will be randomized into either an 8-week Expressive Arts-based intervention group or Treatment-As-Usual control group.
Status | Recruiting |
Enrollment | 154 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility | Inclusion Criteria: - Participants are community-dwelling, Chinese-speaking adults aged between 50 and 80, with the diagnosis of age-related macular degeneration in one or both eyes of all different etiologies Exclusion Criteria: - Inability to understand the Chinese language, as well as a diagnosis of total blindness, presence of other significant physical, psychological, and cognitive comorbidities that would hinder the participant from completing the study will be excluded. |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Centre on Behavioral Health, The University of Hong Kong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong | The Hong Kong Polytechnic University, The Hong Kong Society for the Blind |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of Baseline Psychosocial Adaptation Questionnaire for visual impairment level at 2 months, 5 months, and 8 months | Administration of the Chinese translated version of the 38-item Psychosocial Adaptation Questionnaire:
The first factor was attitude, involving 10 items. The second factor was self-acceptance, involving six items. The third factor was self-esteem involving six items. The fourth factor was anxiety/depression, involving six items. The fifth factor was belonging, involving five items. The sixth factor was self-efficacy involving three items. The last factor was the sense of self-control, involving two items. Higher scores indicate a higher level of endorsement in a specific domain. Likert's scale with four points was used to quantify results. The four points included completely incorrect, more correct, most correct, and completely correct. The score for positive items was one point, two points, three points, and four points; negative items were scored oppositely. Q14, Q17, Q19, Q20, Q21, Q22, Q29, Q30, Q31, and Q32 are reversed (positive) items. |
Baseline, post-intervention (Month 2), 3-month post-intervention (Month 5), and 6-month post-intervention (Month 8) | |
Primary | Change of Baseline Vision-related Quality of Life level at 2 months, 5 months, and 8 months | Administration of the Chinese translated version of the 13-item Vision-related Quality of Life Scale:
Vision-specific quality of life is measured by the 13-item Vision-Related Quality of Life Scale taken from 25-item National Eye Institute Visual Function Questionnaire. Social functioning of Vision-specific quality of life is Q11 and Q13 respectively. Mental health of Vision-specific quality of life is Q3, Q25, Q21, and Q22 respectively. Role limitation of Vision-specific quality of life is Q17 and Q18 respectively. Dependency of Vision-specific quality of life is Q20, Q23, and Q24 respectively. Ocular pain of Vision-specific quality of life is Q4 and Q19 respectively. Original numeric values from the survey are re-coded following the scoring rules. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 1 |
Baseline, post-intervention (Month 2), 3-month post-intervention (Month 5), and 6-month post-intervention (Month 8) | |
Secondary | Change of Baseline Anxiety level at 2 months, 5 months, and 8 months | Administration of the Chinese translated version of the Hospital Anxiety and Depression Scale.
This scale is adopted to measure the level of Anxiety. The minimum score is 0 and the maximum score is 21. Scores ranging from "0-7" represents "Normal", ranging from "8-10" represents "Borderline abnormal", and ranging from "11-21" represents "Abnormal". |
Baseline, post-intervention (Month 2), 3-month post-intervention (Month 5), and 6-month post-intervention (Month 8) | |
Secondary | Change of Baseline Depression level at 2 months, 5 months, and 8 months | Administration of the Chinese translated version of the Hospital Anxiety and Depression Scale.
This scale is adopted to measure the level of Depression. The minimum score is 0 and the maximum score is 21. Scores ranging from "0-7" represents "Normal", ranging from "8-10" represents "Borderline abnormal", and ranging from "11-21" represents "Abnormal". |
Baseline, post-intervention (Month 2), 3-month post-intervention (Month 5), and 6-month post-intervention (Month 8) | |
Secondary | Change of Baseline Resilience level at 2 months, 5 months and 8 months | Administration of the Chinese translated version of the self-report Resilience Scale-14.
The brief "RS-14 scale consists of 14 self-report items measured along a 7-point rating scale ranging from '1-strongly disagree' to '7-strongly agree.' Higher scores are indicative of resilience level. Scores are calculated by a summation of response values for each item, thus enabling scores to range from 14 to 98. Scores below 65 indicate low resilience; between 65 and 81 show moderate resilience; above 81 will be interpreted as high levels of resilience. |
Baseline, post-intervention (Month 2), 3-month after post-intervention (Month 5), and 6-month after post-intervention (Month 8) | |
Secondary | Change of Baseline Perceived Social Support level at 2 months, 5 months and 8 months | Administration of the Chinese version of the Multidimensional Scale of Perceived Social Support
This scale has adopted the measure the level of perceived social support from family, friends, or significant other. The mean score of perceived social support from "family" is calculated by summing across Q3, Q4, Q8, and Q11, then divide by 4 values. The mean score of perceived social support from "friends" is calculated by summing across Q6, Q7, Q9, and Q12, then divide by 4 values. The mean score of perceived social support from "significant other" is calculated by summing across Q1, Q2, Q5, and Q10, then divide by 4 values. The mean total score is calculated by summing across all 12 items, then divide by 12 values. The minimum mean score of each sub-score and the total score is 1 and the maximum mean score is 7. |
Baseline, post-intervention (Month 2), 3-month after post-intervention (Month 5), and 6-month after post-intervention (Month 8) | |
Secondary | Change of Baseline Imagination level at 2 months, 5 months, and 8 months | Administration of the Chinese translated version of the Self-Descriptive Imagination questionnaire.
The Self-Descriptive Imagination Questionnaire consists of 25 items. Expressive imagination is Q4, Q5, Q12, Q7, and Q13 respectively. Openness to variations is Q16, Q19, Q17, and Q23 respectively. Instrumental imagination is Q8, Q11, and Q10 respectively. Past/future mindedness is Q2, and Q1 respectively. Conventionality is Q24 and Q25 respectively. The questionnaires measured along a 7-point rating scale ranging from '1- strongly disagree' to '7-strongly agree.' Scores are calculated by a summation of response values for each item, Higher scores are indicative of imagination level. |
Baseline, post-intervention (Month 2), 3-month after post-intervention (Month 5), and 6-month after post-intervention (Month 8) | |
Secondary | Change of Baseline Imagination level at 2 months, 5 months, and 8 months | Administration of the Chinese translated version of the Fantastic Reality Ability Measurement.
The Fantastic Reality Ability Measurement consists of 21 items. Coping is Q4, Q8, Q15, and Q20 respectively. Transcendence is Q17, Q10, Q21, Q12, Q18, and Q7 respectively. Playfulness is Q5, Q6, Q9, Q14, Q19, and Q2 respectively. Control is Q11, Q13, Q3, Q16, and Q1 respectively. The questionnaires measured along a 7-point rating scale ranging from '1- strongly disagree' to '7-strongly agree.' Scores are calculated by a summation of response values for each item, Higher scores are indicative of imagination level. |
Baseline, post-intervention (Month 2), 3-month after post-intervention (Month 5), and 6-month after post-intervention (Month 8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |